Bcal Diagnostics Hits 9: month high on ethics approval in Australia

BCAL Diagnostics

03/12/2025 02:33

** BCAL Diagnostics BDX.AX jumps as much as 9.1% to A$0.12, highest since February 24

** Diagnostics firm gets national ethics approval in Australia for a registry study on up to 24,000 women where subjects will use co's breast cancer screening product BREASTESTplus as part of their clinical treatment

** CEO says registry will accelerate doctor adoption while collecting real-world data to support future reimbursement

** YTD, BDX gains 13.4%

 (Reporting by Shruti Agarwal in Bengaluru)

 ((Shruti.Agarwal@thomsonreuters.com))